CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that members of its senior leadership team will participate in one-on-one meetings with investors at the upcoming Citi 17th Annual BioPharma Conference taking place on September 7-8, 2022, in Boston, MA.
For additional information or to schedule a one-on-one meeting with members of the Oak Hill management team, please contact your Citi representative.
About Oak Hill Bio
Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The company, which has operations in the United States and United Kingdom, was launched to develop a pipeline of six promising clinical-stage and preclinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited (“Takeda”). For more information on Oak Hill Bio, visit the company’s website at www.oakhillbio.com.
